New techniques have introduced unprecedented sensitivity to the investigation of the gut microbiota, enabling insights into the discrete contributions of select bacterial species and advancing our mechanistic appreciation of the roles of diet and host immunity in limiting or enabling metabolic and inflammatory disease.
fatty liver has accelerated so precipitously in less than a generation. It is increasingly likely that broad changes in our microbiome composition-perhaps influenced by diet, environment, genetics or antibiotic usagehave created this relatively new disease. 6 Second, they suggest that new therapeutic avenues might attempt to alter the microbiota in an effort to attenuate the chronic inflammation associated with metabolic syndrome and fatty liver, perhaps using probiotics or narrow-spectrum antibiotics. Given the tremendous number of bacteria that inhabit the human colon, it is remarkable that their contribution to health and disease has been overlooked for so long.
Turning to human rather than experimental NASH, two related studies have used immunohistochemistry of liver biopsy specimens to implicate hedgehog signalling and progenitor cell activation in the patho genesis of NASH fibrosis. The first study from Guy and colleagues 7 exploits the availability of a large number of biopsy samples generated by the NIH NASH Clinical Research Network to assess the relative activity of the hedgehog pathway. This molecule was initially identified as a develop mental morphogen, but is now also implicated in adult diseases, especially cancer. 8 Staining for sonic hedgehog protein, one of three major hedgehog ligands in vertebrates, was increased in portal cells (especially bile duct cells) and was correlated with fibrosis stage and hepatocyte ballooning, based on the well-validated NASH histologic scoring system. Concurrently, expression of GLI2 (a hedgehog-regulated target gene) was increased in cells that also expressed K7 (also called CK7), which is thought to mark a subpopulation of epithelial progenitors. GLI2 was also expressed in stromal cells that expressed vimentin. These findings suggest that increased hedgehog signalling, derived from bile ductular cells and acting upon progenitor and stromal cells (including activated stellate cells), somehow promotes fibrosis, but the mechanism is not fully clarified.
In a complementary study, Nobili and colleagues 9 used CK7 staining to examine the hepatic progenitor response in 30 children with NAFLD. The number of hepatic progenitor cells correlated with the degree of fibrosis in these patients, 9 and the progenitor cells also expressed the adipogenic hormones adiponectin, resistin and glucagon-like peptide 1. These findings are similar to previous studies implicating the 'ductular reaction' , which involves progenitor cell expansion in hepatic fibrosis.
Together these two descriptive studies by Guy et al. 7 and Nobili et al. 9 ■ Altered composition of the gut microbiota might contribute to NASH pathogenesis, leading to increased hepatic injury and fibrosis 4, 5 ■ Progressive fibrosis in NASH is associated with increased activity of hedgehog signalling in the liver, in conjunction with the appearance of cells that express progenitor cell markers 7, 9 fibrosis in NAFLD and NASH, a clinical problem that is certain to cause rising morbidity and mortality unless new therapeutic prospects emerge. The human intestinal tract is inhabited by ~100 trillion bacteria, comprising at least 3,000 distinct species-the gut microbiota.
This diverse microbial community has an important role in metabolism and immunity and is increasingly appreciated as a central 'environmental factor' in numerous diseases, including IBD, metabolic syndrome and cancer. As such, manipulation of the gut microbiota could represent a novel means to treat these increasingly common inflammatory diseases. Herein, we review some of the key areas of progress in this endeavour in 2012. Previous studies have shown that changes in microbiota composition correlate with development of deleterious inflammatory and metabolic phenotypes that can be transferred upon microbiota transplant. Such work has fostered a phenomenological appreciation of the microbiota's influence, but advances in analytical chemistry (especially nucleic acid sequencing technologies) have enabled interrogation of species-level contributions to the microbiota ecosystem and overall host health; a striking example is the demonstration that a diet containing only milk-derived fats promotes dramatic expansion of Bilophila wadsworthia (a sulphite-reducing bacteria), owing to a milk-fat-induced increase in biliary taurine. 1 This bloom of a normally undetectable bacterial species was accompanied by an enhanced T-helper-1 immune response, induced colitis in Il10-deficient mice and conferred sensitivity to induction of colitis in wild-type mice. This work is the first (of probably many) to report specific diet-host-microbe interactions capable of causing dysbiosis that interlink metabolic and inflammatory changes.
States of chronic inflammation (colitis) have long been associated with cancer, although mechanistic links remain poorly defined. Although inflammation-associated oxidant production was presumed to be the major means of inducing DNA damage-the key driver of carcinogenesis-findings from 2012 reveal that such damage is also exacerbated by genotoxin-producing Escherichia coli.
2 Such bacteria increased in relative abundance after the initiation of inflammation and were associated with colon cancer in both humans and mouse models. This work underscores the multifactorial and interrelated nature of microbiota-mediated disease as inflammation promotes DNA damage primarily and by facilitating the growth of genotoxic bacteria.
Development of host-microbiota symbiosis is perhaps the most ancient and central evolutionary process; proper manage ment of the microbiota is essential for basic daily survival. Indeed, considering that the gut represents a roughly tenniscourt-sized interface with the outside world, immunity and metabolism are, by necessity, tightly intertwined. Loss of B-cell-derived IgA results in a dysregulated microbiota that requires a compensatory immune response from intestinal epithelial cells. 3 This shift away from normal Gata4-mediated metabolic function in favour of enhanced interferon-inducible immune pathways results in undernourishment (specifically impaired lipid absorption) with gene expression resembling that seen in immunodeficient and HIV-positive humans. 3 The opposite scenario, that of malnutrition causing dysbiosis, has now been mechanistically established. Mice lacking angiotensin 1 converting enzyme 2 have impaired absorption of neutral amino acids (including tryptophan), resulting in colitis and diarrhoea that mimics the human disease pellagra. 4 Such mal absorption also caused dysbiosis via mTOR-mediated reduction in antimicrobial peptide secretion in the small intestine, which could be rescued with supplementation with tryptophan or the metabolic end product nicotin amide. This work suggests that a variety of metabolic deficiencies feature, at least in part, dysregulation of the microbiota and might thereby be ameliorated through careful manipulation of resident bacteria and/or immunity.
The treatment of overnutrition, however, is of greater interest to the developed world, which faces an epidemic of metabolic syndrome related to increased consumption and reduced physical activity. Metabolic syndrome is promoted by loss of inflammasome signalling. Deletion of Nlrp3 or Nlrp6 in mice results in an altered microbiota capable of exacerbating the development of metabolic syndrome via increased levels of Toll-like receptor (TLR)4 and 9 ligands; 5 specifically, increased levels of such ligands in portal circulation promoted TNF-mediated NAFLD development. Interestingly, simply co-housing these immunocompromised mice with wild-type animals conferred the observed predispositions to NAFLD and obesity, with the implication that an altered pathogenic microbiota might be somewhat analogous to an infectious disease. Whilst acknowledging the important caveats of limited study time and use of coprophagic rodents, a similar process could be occurring in humans, especially in family groups cohabitating for extended periods.
A study of Tlr5-deficient mice indicates that the state of microbiota flux itself might promote inflammation and dysmetabolism in general rather than the presence or absence of particular bacterial species or genes. 6 Some Tlr5-deficient mice develop colitis whereas others develop low-grade inflammation and metabolic syndrome without colitis and, whilst overall penetrance is stable from generation to generation, the development of colitis occurs randomly. Weekly sampling of faecal bacteria revealed that, unlike wild-type mice, Tlr5-deficient mice had increased weekto-week changes to the microbiota and that such volatility was observed whether or not mice eventually developed colitis. This phenomenon, wherein the host must engender a compensatory response to attempt to control microbiota composition, could reflect human IBD, which is promoted by disparate innate immune deficiencies but in which at least half of overall disease risk is dictated by nongenetic (environmental) factors. Furthermore, in these mice, transient colonization by normally undetect able speciesa human Crohn's-disease-associated E. coli strain-promoted chronic inflammation and colitis that persisted well after clearance, suggesting that uncontrolled volatility could promote inflammation simply by allowing deleterious species the opportunity to interact with the host. Studies in humans, though enlightening, would require longterm repeat sampling starting well before IBD develops.
Given that the increasing prevalence of IBD and obesity has occurred recently in evolutionary terms, the contribution of host genetics to such population-level microbiota changes is probably fairly minor. Rather, societal and technological progress has reoriented the host-microbiota axis. One possible culprit is the widespread use of antibiotics by both humans and large-scale farming operations that have routinely used low-dose anti biotics to stimulate weight gain 
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for >50 years. Young mice exposed to single or combination antibiotic therapy exhibit lasting increases in adiposity and accelerated bone mineral deposition; whilst total bacterial numbers remained similar to untreated mice, the composition of the microbiota was altered substantially. 7 Notably, expansion of the phylum Firmicutes and contraction of Bacteriodetes, a shift that generally accompanies weight gain in a variety of models, was observed. 7 Furthermore, bacterial expression of genes related to carbo hydrate metabolism was altered, resulting in increased energy extraction and hepatic lipogenesis. 7 Interestingly, changes in the microbiota that promote adiposity could have a normal physiological role, to increase energy extracted from food throughout pregnancy and lactation. 8 Indeed, by delivery, pregnant women develop many of the hallmarks of metabolic syndrome: adiposity; insulin resistance; increased bacterial load with reduced diversity; and an altered Firmicutes:Bacteriodetes ratio. Moreover, microbiota from a third trimester woman induced a similar metabolic phenotype when transferred to germ-free mice. 8 These data suggest that metabolic syndrome mimics, or even co-opts, evolved mechanisms designed to increase energy extraction during the most metabolically demanding phases of reproduction.
Despite our basic understanding of the specific mechanisms underlying metabolic syndrome, treatment avenues do exist. A well-controlled clinical trial designed to manipulate the microbiota to treat insulin resistance (a hallmark of metabolic syndrome) achieved remarkable success. 9 Small intestinal infusion of gut bacteria from lean donors increased sensitivity to insulin within 6 weeks without changes in diet, hormone profile or total number of bacteria; controls given their own microbiota showed no improvement. Consistent with experimental work, an increase in microbiota diversity, with notable expansion of butyrate-producing bacteria, was observed. Thus, although still in very early stages, the development of techniques that replace or augment the host's microbiota hold notable promise for the treatment of metabolic disease and could be extended to treat any number of gut-linked dis orders (including IBD). Indeed, increasingly fine techniques that enable interrogation and manipulation of the microbiota might presage next-generation treatment regimes that are both personalized and act through existing natural pathways.
Research from 2012 has begun to reveal some of the specific molecular mechanisms by which diet and host immunity determine microbiota composition. Researchers have also made substantial headway in understanding how specific bacteria contribute to a broad array of intestinal disease states. An emerging central theme is that host defence and metabolism are highly intertwined with innate immunity and inflammation, serving as a key interface of these crucial biological processes. 2012 has also seen major pro gress in the identification and examination of societal factors that have eroded the established distinction between commensal and pathogen and established a nuanced relationship between host and symbiont, as well as proof that interventional therapy represents an avenue by which to reassert host control over the microbiota. Given the increasing appreciation of the relevance of gut bacteria in host health, methods of establishing and maintaining such control holds great promise as treatment for a variety of heretofore intractable chronic intestinal diseases. 
